Fusion Antibodies plc (AIM: FAB), a Belfast-based specialist in pre-clinical antibody discovery and engineering, announced on Wednesday that it has been awarded a new multi-target Integrated Therapeutic Antibody Services project by the Antibody Centre of Excellence of a European-based global pharmaceutical company under a Master Service Agreement signed earlier this year.

The project covers antibody humanisation, expression, purification and supply, with Fusion set to humanise a family of VHH antibody fragments for the client. Work is expected to conclude within the current financial year, generating revenues of at least GBP175,000.

Fusion said the contract win reinforces its position as a trusted partner for major pharmaceutical companies and aligns with its strategy to diversify its client base, reduce exposure to smaller, more volatile customers, and leverage proprietary technologies such as OptiMAL to drive sustainable growth.

Established in 2001 as a spin-out from Queen's University Belfast, Fusion Antibodies provides a comprehensive suite of antibody generation and optimisation services to global pharmaceutical and diagnostic firms. The company has completed more than 285 humanisation projects and worked with eight of the world's top ten pharmaceutical companies by revenue.